key: cord-0984805-h1izlkst
authors: Ferreras, C; Pascual-Miguel, B; Mestre-Durán, C; Navarro-Zapata, A; Clares-Villa, L; Martín-Cortázar, C; De Paz, R; Marcos, A; Vicario, JL; Balas, A; García-Sánchez, F; Eguizabal, C; Solano, C; Mora-Rillo, M; Soria, B; Pérez-Martínez, A
title: SARS-CoV-2 specific memory T lymphocytes from COVID-19 convalescent donors: identification, biobanking and large-scale production for Adoptive Cell Therapy
date: 2020-10-26
journal: bioRxiv
DOI: 10.1101/2020.10.23.352294
sha: 71b29a3c6f679bde0ad20c5d1bd774781b869ff9
doc_id: 984805
cord_uid: h1izlkst

SARS-CoV-2 is causing a second outbreak so the hope for its complete eradication is far from happening. In the absence of effective vaccines, it is mandatory to find effective treatments with low adverse effects able to treat hospitalized patients with COVID-19 disease. In this work, we determined the existence of SARS-CoV-2 specific T cells within the CD45RA− T memory cells from the blood of convalescent donors. Memory T cells can respond quickly to the infection and provide long-term immune protection to reduce the severity of the COVID-19 symptoms. Also, CD45RA− memory T cells confer protection from other pathogens the donors encountered in their life. This is vital to clear other secondary infections usually developed in hospitalized COVID-19 patients. SARS-CoV-2 specific memory T cells were found within all the CD45RA− subsets CD3+, CD4+, CD8+, and in the central memory and effector memory subpopulations. The procedure to obtain the cells is feasible, easy to implement for small scale manufacture, quick and cost-effective involving minimal manipulation, and without GMP condition requirements. This biobank of specific SARS-CoV-2 memory T cells would be immediately available ‘off-the-shelf’ to treat moderate/severe cases of COVID-19 increasing the therapeutic options available for these patients.

The new severe acute respiratory syndrome coronavirus 2, or SARS-CoV-2 has emerged causing a worldwide pandemic from late 2019. This coronavirus is causing an infectious disease called COVID-19 with a wide range and diverse symptoms. In most infected patients the illness generates mild symptoms including fever and cough but, in some others, causes a life-threatening disease with symptoms that include pneumonia, dyspnea and a hyperinflammatory process which includes cytokine storm, systemic immunethrombosis, etc. Patients suffering from these symptoms need hospitalization and treatment. A common feature of this severe disease is lymphopenia making them more vulnerable to co-infections and correlating with the severity of the disease 1,2 . With strong restrictive measures, social distancing, and healthcare interventions the first wave was contained, although thousands of patients died. Far from disappearing SARS-CoV-2 is causing a second wave thus diminishing the hope of its complete eradication.

Vaccine development actively pursues to generate active immunity through vaccine immunization 3 but there is uncertainty about how long antibody-mediated immune response to COVID-19 will last 4 . We need effective treatments that can reduce the severity of symptoms, time of hospitalization and increase survival.

So far, the only treatment for COVID-19 is supportive. Antiviral treatment with lopinavir-ritonavir is not effective in improving outcomes for hospitalized patients with COVID-19 5 ; also, remdesivir has been recently approved to treat COVID-19 although its beneficial effect is still controversial 6, 7 . Preliminary results with anti-inflammatory therapies such as dexamethasone 8 or mesenchymal stromal cells 9 have shown promising results for critical patients (WHO Grade 6 and 7) 10 , but we do not have yet an effective antiviral therapy able to stop the progress of this diseases at early stages: (WHO Grade 1-4 moderate and severe) or even to prevent COVID-19.

The role of the adaptive immunity in COVID-19 disease and the protective immunity conferred by T cells is being characterized [11] [12] [13] [14] [15] Memory T cells do appear when T lymphocytes recognize a pathogen presented by their local antigen-presenting cells. These T cells activate, proliferate, and differentiate into effector cells secreting molecules to control the infection. Once the pathogen has been cleared most of the antigen-specific T cells disappear and a pool of heterogeneous longlived memory T cells persist 22,23 . This population of memory T cells defined as CD45RAor CD45RO + is maintained over time conferring a quick and long-term immune protection against subsequent reinfections 24,25 .

In this work, we report the existence of a SARS-CoV-2 specific T cell population within the CD45RA -T memory cells from the blood of convalescent donors that can be easily, effectively, and rapidly isolated by CD45RA depletion. These specific SARS-CoV-2 CD45RA -T memory cells may be able to clear virally infected cells and to confer T cell immunity for subsequent reinfections. These cells can be stored to be used in moderate and severe cases of hospitalized COVID-19 patients becoming an off-the-self living drug.

Donors' characteristics Table 1 shows the donors' characteristics. Six COVID-19 convalescent donors and two healthy controls were included. The convalescent donors were all tested for SARS-CoV-2 by reverse-transcriptase polymerase chain reaction (RT-PCR) in nasopharyngeal samples between March and April 2020. Eligibility criteria included age 21 to 65, a history of COVID-19 with documented positive RT-PCR test for SARS-CoV-2. At the time of this study, they were all tested negative for SARS-CoV-2. The median age of the convalescent donors was 37 years old (range 23-41), three were females and three were males. The median days until PCR negative for SARS-CoV-2 was 13 days (range 5-17). Two of them presented with bilateral pneumonia but no hospitalization was needed. Just one of them received treatment with oral hydroxycloroquine + azytromicine + lopinariv/ritonavir and another one was treated with oral hydroxycloroquine + azytromicine. Two healthy donors were enrolled who have not been exposed to COVID-19 patients and were tested negative for anti-SARS-CoV-2 antibodies in June 2020. All the participants gave written consent with approval by the Hospital Institution Review Board (IRB number: 254/20) 

PBMCs of the convalescent and healthy donors were stimulated with the three overlapping peptides (M, N, S) specific of SARS-CoV-2 for 5 hours. We detected the existence of SARS-CoV-2 specific population by the production of IFN- in both subsets naïve CD45RA + and memory CD45RA -T cells in the PBMCs of the convalescent donors but not in healthy controls (Table 2 and Figure 1 ). They also showed reactivity for the single peptides M, N, and S (data not shown). The mean CD45RA -CD3 + population in the convalescent donors was close to 90%. Expression of IFN-within CD45RA -CD3 + population was 1.12% whereas the expression of IFN-within CD45RA + CD3 + population was 0.40% (P=0.065) ( Table 2) . We didn't detect the expression of IFN- in healthy individuals. Despite is a small cohort we didn't find a synergistic effect on the percentage of IFN- when the three peptides are mixed when compared to the single peptides (data not shown).

Identification of SARS-CoV-2 specific CD4 + T and CD8 + T cell responses within CD45RAmemory T cells Then, we asked whether both CD8 + and CD4 + subsets contained specific SARS-CoV-2 T cells within the PBMCs of the convalescent donors. Among all subsets studied we observed that CD45RA -CD4 + and CD45RA -CD8 + cells expressed 1.25% and 0.85% of IFN-respectively (P= 0.132). (Table 2, Figure 2 , and data not shown). Thus, all the convalescent donors recovered from COVID-19 generated CD4 + T and CD8 + T cells responses against SARS-CoV-2 within the memory CD45RA -T cell population.

We then analysed the T central memory (CM) (CD45RA -CD3 + CD27 + ) and T effector memory (EM) (CD45RA -CD3 + CD27 -) compartments. While no significant differences were detected, we observed responses to the SARS-CoV-2 specific peptides within all subpopulations. Within the CD4 + and CD8 + CM T cell subsets we detected a mean of 1.26% and 0.79% of IFN-  cells respectively (P=0.132). Looking at the CD4 + and CD8 + EM T cell subsets we detected a mean of 1.25% and 1.06% of IFN-  cells respectively (P=0.108). ( Table 2 and Figure 3 ). These data show the existence of a population of memory T cells specific for SARS-CoV-2 within the CD45RA -CD3 + memory T cells.

Large-scale CD45RA depletion. Creation of an off-the self-biobank of CD45RAmemory T cells from a COVID-19 convalescent donor Blood donor apheresis was performed followed by CD45RA + T cell depletion as described in Material and Methods. After depletion of CD45RA + cells, 99.8% of the cells were CD45RA -CD3 + . Cells were cryopreserved and stored. Most of the CD45RO + cells were CD4 + with a high CD4/CD8 ratio. The viability after thawing was 98-99%.

Identification of SARS-CoV-2 specific CD4 + T and CD8 + T cell responses within

After CD45RA depletion, the percentage of CD45RA -CD3 + cells was 80.05%. Within that population 83.56% of the cells were CD4 + and 14.37% were CD8 + T cells. After exposure to the three peptides specific for SARS-CoV-2, we found that CD3 + , CD3 + CD4 + , and CD3 + CD8 + subsets expressed IFN- with percentages of 0.36, 0.38, and 0.31 respectively. (Table 3) .

Within the EM and CM compartments, most of the CD4 + and CD8 + cells had a CM phenotype (89.1% v 61.6%). Both subpopulations CM and EM expressed IFN- after exposure with the three peptides. Within CD4 + CM, CD8 + CM and CD4 + EM subsets we found that 0.38%, 0.70% and 0.39% of cells respectively expressed IFN-. We didn't find a specific expression of IFN- within the CD8 + EM subset. (Table 3) .

Then, we characterized in-depth the phenotypic expression of activation, exhaustion, and Treg markers within the CD45RApopulation of the convalescent donor. The number of Treg defined by CD127 low CD25 + was 11.26%. We found that the CD45RA -CD3 + expressed the activation marker HLA-DR (19.40%) in both subsets of cells CD4 + (16.70%) and CD8 + (29.19%) . After exposure to the three SARS-CoV-2 specific peptides we found that within CD3 + HLA -DR + , CD4 + HLA -DR + , and CD8 + HLA-DR + populations 0.93%, 0.70% and 1.21% of the cells respectively were IFN- + . Also, the CD45RA -CD3 + expressed the exhaustion marker NKG2A (1.88%) and this expression was 10.24% within the CD8+ subset whereas it was nearly undetectable in CD4 + cells (0.14%). We didn't find expression of IFN- within the NKG2A + population. Also, 0.70% of the CD45RA -CD3 + cells expressed the exhaustion marker PD-1, this expression was 1.43% within the CD4 + subset and 0.13% within the CD8 + cells. We found 0.62% of IFN- + cells within the CD45RA -CD3 + CD4 + PD-1 + population after exposure to the three peptides. (Table 3 ).

Polyclonal distribution for both TCR- and - CDR3-encoding regions was almost identical among control and CD45RA -, whereas different oligoclonal fragments were seen in the CD45RA + population. Three of the oligoclonal fragments seen in CD45RA + cells were also identified in CD45RA - (Figure 4) .

Induction of an activated memory T cells phenotype within CD45RAmemory T cells after CD45RA depletion IL15 is a cytokine fundamental for memory T cells that induces the activation, proliferation, and survival of T cells. To induce an activated phenotype of memory T cells we incubated the CD45RA-T cells with IL15 o/n and for 72 hours ( Table 3) . We observed a fold increase of the activation markers HLA-DR, CD69, and CD25 after 72 h of incubation (2.63, 29.59, 8.52) when compared to o/n incubation (1.15, 3.18, 1.50 ).

The expression of the exhaustion markers NKG2A and PD-1 were also higher after 72 hours of incubation ( Supplementary Figures 1-5) . Then, we looked at the expression of chemokine CCR7 and the integrin CD103 important for homing to the air tract respiratory 26,27 . We observed that most of the CD3 + CD4 + cells expressed CCR7 + cells (88.13%) and the CD3 + CD8 + subpopulation expressed 45.42% of CCR7 + cells. The expression of CD103 was low in peripheral blood as expected 26 . We detected that the expression in the CD3 + CD103 + , CD3 + CD8 + CD103 + and CD3 + CD4 + CD103 + compartments was 2.18%, 5.96% and 1.38% respectively. Although the fold increase was not very remarkable in the CD45RA -CD3 + cells after 72 hours of incubation (1.00fold CCR7 and 1.24-fold CD103), the increase was higher (1.40) within the CD8 + subpopulation ( Table 3 and Supplementary Figures 6, 7) .

In the absence of an effective vaccine, and with the emergence of a second wave there is an urgent need to find effective treatments for COVID-19 disease. Here we report the existence of a SARS-CoV-2 specific T cell population within the CD45RA -T memory cells of the blood from the convalescent donors. These cells can be easily, effectively, and rapidly isolated following a donor selection strategy based on the expression of IFN- after exposure with SARS-CoV-2 specific peptides and HLA antigen expression.

This way we can obtain clinical-grade CD45RAmemory T lymphocytes from the blood of convalescent donors, biobanking, thawing, and using them as a treatment for moderate/severe cases of COVID-19. These so-called "living drugs" retain memory against SARS-CoV-2 and other pathogens they have encountered previously. Unlike plasma where the concentration decreases after infusion, memory T cells expand and proliferate, so we hypothesize that will have a more lasting effect.

In previous studies this population of CD45RAmemory T cells have shown no alloreactivity when compared to the CD45RA + counterpart 28 , they are mainly CD4 +29 and they have shown to be effective against viral infections 20 . Phenotypically we found that CD45RAmemory T cells were fully capable of producing IFN- in the presence of SARS-CoV-2 specific peptides. Both CD4 + and CD8 + CM and EM subsets were able to In our study, we did not observe the production of IFN- by SARS-Cov-2 specific T cells in healthy unexposed individuals which is in agreement with the data from Peng Y et al 34 but differs from previously published data 14 . This could also due to the different detection methods used and the small sample size.

Studies have shown that the correlation between neutralizing antibodies and the severity of the symptoms where antibody responses wane over time even in a short period as 6-7 weeks after the onset of symptoms [35] [36] [37] . Importantly our data shows the existence of the SARS-CoV-2 memory T cells in convalescent donors with mild symptoms. This has a great implication for the protection from the next SARS-CoV-2 infections and to decrease the severity of COVID-19 disease. Further studies with a larger cohort to determine the duration of memory to SARS-CoV-2 will be needed to elucidate longterm protection to SARS-CoV-2 as it has been shown for another coronavirus previously 16 .

For the proper T cell recognition, both donor and recipient need to share HLA alleles.

Given the vast number of convalescent donors to find a right haploidentical donor based on HLA typing would not be difficult. We estimate that based on HLA donor-recipient match four donors will cover almost the whole country population 38 .

The procedure to obtain the cells is easy to implement for small scale manufacture, quick and cost-effective involving minimal manipulation and without GMP condition requirements. These factors make feasible the generation of a biobank or stock from the blood of convalescent donors that would be immediately available 'off the shelf' for subsequent outbreaks of the pandemic increasing the therapeutic options available in the current SARS-CoV-2 pandemic. The safety of these cells in moderate/severe patients with COVID-19 is currently assessed in a clinical trial (NCT04578210).

These cells could provide to the patient: 1) a pool of SARS-CoV-2 specific T cells that Supplemental Figure 2 . Expression of CD69 in the CD45RA -CD3 + , CD45RA -CD3 + CD4 + and CD45RA -CD3 + CD8 + populations from the convalescent donor. Cells were culture with 50 ng/ml of IL15 o/n and for 72 hours.

Supplemental Figure 3 . Expression of CD25 in the CD45RA -CD3 + , CD45RA -CD3 + CD4 + and CD45RA -CD3 + CD8 + populations from the convalescent donor. Cells were culture with 50 ng/ml of IL15 o/n and for 72 hours.

Supplemental Figure 4 . Expression of NKG2A in the CD45RA -CD3 + , CD45RA -CD3+CD4 + and CD45RA -CD3 + CD8 + populations from the convalescent donor. Cells were culture with 50 ng/ml of IL15 o/n and for 72 hours.

Supplemental Figure 5 . Expression of PD-1 in the CD45RA -CD3 + , CD45RA -CD3 + CD4 + and CD45RA -CD3 + CD8 + populations from the convalescent donor. Cells were culture with 50 ng/ml of IL15 o/n and for 72 hours.

Supplemental Figure 6 . Expression of CCR7 in the CD45RA -CD3 + , CD45RA -CD3 + CD4 + and CD45RA -CD3 + CD8 + populations from the convalescent donor. Cells were culture with 50 ng/ml of IL15 o/n and for 72 hours.

Supplemental Figure 7 . Expression of CD103 in the CD45RA -CD3 + , CD45RA -CD3 + CD4 + and CD45RA -CD3 + CD8 + populations from the convalescent donor. Cells were culture with 50 ng/ml of IL15 o/n and for 72 hours. The media value after 5 hours exposure of the three SARS-Cov-2 peptides (M,N,S) is shown. SD: Standard deviation; C= healthy controls; D= convalescent donors; Pepx3= mixture of the single SARS-Cov-2 peptides M,N,S 

Dysregulation of Immune Response in Patients With Coronavirus

Lymphopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: A systematic review and meta-analysis Int J Infect Dis

The COVID-19 vaccine development landscape

Zhang M et al T cell responses to whole SARS coronavirus in humans

Antiviral monotherapy for hospitalised patients with COVID-19 is not enough

Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial

Clinical efficacy of antivirals against novel coronavirus (COVID-19

Dexamethasone in Hospitalized Patients with Covid-19 -Preliminary Report

Adipose-derived mesenchymal stromal cells for the treatment of patients with severe SARS-CoV-2 pneumonia requiring mechanical ventilation. A proof of concept study

World Health Organization. World Health Organization and R&D Blueprint strategy for COVID-19

Rapid production of clinical-grade SARS-CoV-2 specific T cells

Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals

Thouvenel C et al Functional SASR-CoV-2-specific immune memory persists after mild COVID-19

Cytotoxic CD4 T Cells-Friend or Foe during Viral Infection? Front. Immunol

Human memory T cells: generation, compartmentalization and homeostasis Nat Rev Immunol

Novel roles for IL15 in T cell survival F1000

IL15 trans-presentation regulates homeostasis of CD4+

Broad and strong memory CD4 + and CD8 + T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19

Hemmings O et al Longitudinal evaluation and decline of antibody responses in SARS-CoV-2 infection doi

Rapid Decay of Anti-SARS-CoV-2 Antibodies in Persons with Mild Covid-19

Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections

Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation

infection with respiratory pathogens among COVID-2019 cases

Rates of Co-infection Between SARS-CoV-2 and Other Respiratory Pathogens JAMA

We thank the donors for their blood donation and the CRIS Cancer Foundation (http://criscancer.org) and the Generalitat Valenciana AVI-GVA COVID-19-68 for their support.

CF, BS and AP-M filed a patent on this topic. BS received fees from Celgene, Gilead, Sanofi and Novo-Nordisk not related to this work.